Cost–effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden

References

• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest133(6. Suppl.), 381S–453S (2008).
   PubMed Web of Science ®Google Scholar
• Milbrink J, Bergqvist D. The incidence of symptomatic venous thromboembolic events in orthopaedic surgery when using routine thromboprophylaxis. Vasa37(4), 353–357 (2008).
   PubMedGoogle Scholar
• Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet372(9632), 31–39 (2008).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med.358(26), 2776–2786 (2008).
   PubMed Web of Science ®Google Scholar
• Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br. J. Surg.83(11), 1548–1552 (1996).
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Bergqvist D, Jönsson B. Cost–effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur. J. Health Econ.4(4), 254–262 (2003).
   PubMedGoogle Scholar
• Lundkvist J, Bergqvist D, Jönsson B. Cost–effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur. J. Health Econ.8(4), 313–323 (2007).
   PubMedGoogle Scholar
• Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med.358(26), 2765–2775 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AGG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet373(9676), 1673–1680 (2009).
   PubMed Web of Science ®Google Scholar
• The TIFDED Study Group. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis29(6), 310–317 (1999).
   PubMedGoogle Scholar
• Krotenberg R, Adler U, Pomeranz B, Miller JD, Russell MW. Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. Am. J. Phys. Med. Rehabil.80(12), 889–895 (2001).
   PubMedGoogle Scholar
• Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. Am. J. Health Syst. Pharm.64(22), 2349–2355 (2007).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis. Thromb. Res.121(7), 17–24 (2007).
   PubMed Web of Science ®Google Scholar
• Muntz J, Scott DA, Lloyd A, Egger M. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int. J. Technol. Assess. Health Care20(4), 405–414 (2004).
   PubMed Web of Science ®Google Scholar
• Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep-vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J. Thromb. Haemost.5(7), 1438–1443 (2007).
   PubMed Web of Science ®Google Scholar
• Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev.16(3), 155–165 (2002).
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med.350(22), 2257–2264 (2004).
   PubMed Web of Science ®Google Scholar
• The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med.349(18), 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Prandoni P, Villalta S, Bagatella P et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica82(4), 423–428 (1997).
   PubMed Web of Science ®Google Scholar
• Räsänen P, Paavolainen P, Sintonen H et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop.78(1), 108–115 (2007).
   PubMed Web of Science ®Google Scholar
• Andersson S, Björholt I, Nilsson GH, Krakau I. Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden. BMC Fam. Pract.7, 67 (2006).
   PubMedGoogle Scholar
• Björholt I, Andersson S, Nilsson GH, Krakau I. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam. Pract.8, 6 (2007).
   PubMedGoogle Scholar
• Galie N, Torbicki A, Barst R et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J.25(24), 2243–2278 (2004).
   PubMed Web of Science ®Google Scholar
• Wlodarczyk JH, Cleland LG, Keogh AM et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics24(9), 903–915 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics21(7), 477–496 (2003).
   PubMed Web of Science ®Google Scholar
• Gordois A, Posnett J, Borris L et al. The cost–effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost.1(10), 2167–2174 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost–effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics22(9), 605–620 (2004).
   PubMed Web of Science ®Google Scholar
• Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch. Orthop. Trauma Surg.124(8), 507–517 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kwong L, Nutescu E. Cost–effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health9(2), 68–76 (2006).
   PubMedGoogle Scholar
• Annemans L, Minjoulat-Rey MC, De Knock M et al. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium. Acta Clin. Belg.59(6), 346–357 (2004).
   PubMed Web of Science ®Google Scholar
• Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost–effectiveness analysis. Am. J. Cardiovasc. Drugs5(2), 121–130 (2005).
   PubMedGoogle Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J. Am. Med. Inform. Assoc.4(1), 49–56 (1997).
   PubMed Web of Science ®Google Scholar
• Highland KB, Strange C, Mazur J, Simpson N. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest124(6), 2087–2092 (2003).
   PubMed Web of Science ®Google Scholar